Laurus Labs Limited has informed the Exchange about Approval of Scheme of Arrangement

Demerger Ratio AnnouncedStrategic Transactions View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹875.45

prior close

₹887.55

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.4%+1.9% vs market

Pharmaceuticals peers, median of 151sector+0.0%+1.5% vs sector

On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

+0.3

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5-0.4+1.9+0.0+1.5

Next day

+0.2-0.6+0.8-0.2+0.5

-0.2-0.6+0.5-0.6+0.5

-1.0-2.1+1.1-1.6+0.7

-1.7-3.3+1.6-2.7+1.0

-2.3-3.8+1.4-2.3-0.0

-1.8-1.9+0.2-1.4-0.4

15d

+2.3+0.0+2.3-0.4+2.7

+3.1+1.0+2.2+0.1+3.1

+5.7+1.9+3.8-2.6+8.3

+11.8+2.7+9.1-6.6+18.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Laurus Labs' Board has approved a Composite Scheme of Arrangement to reorganize its wholly owned subsidiary Laurus Synthesis Pvt Ltd (LSPL). Under the scheme, Unit-1 of LSPL (CDMO/CRAMS business) will be demerged and merged into Sriam Labs Pvt Ltd (API manufacturing), while the remaining business of LSPL will be amalgamated back into Laurus Labs and LSPL will be dissolved. The appointed date is April 1, 2026, subject to NCLT approval. As consideration for the demerger, Sriam Labs will issue 27 equity shares (₹10 each) to Laurus Labs for every 1 share held in LSPL. For the amalgamation of remaining LSPL into Laurus Labs, no new shares will be issued since LSPL is wholly owned, so there is no change in Laurus Labs' shareholding pattern. The rationale is consolidation of similar businesses, simplification of group structure, and operational efficiencies.

Likely market impact

This is an internal group restructuring among wholly owned subsidiaries and should be largely neutral for Laurus Labs shareholders — no dilution, no cash outflow, and no change in shareholding. The reorganization may improve operational efficiency and business focus, but the actual effect on the stock is expected to be minimal unless execution reveals unexpected synergies or costs.